Connect with the community live

Moderated poster session at UEG Week 2026 on steatotic liver disease (SLD): detection, disparities and the impact of treatment from clinical and public health perspectives. Topics: hepatobiliary, primary care. Chairs: Maurice Michel (Germany) and Nicola Pugliese (Italy). Part of UEG Week 2026 in Barcelona.

Moderated poster MP0333 at UEG Week 2026, presented by Maurice Michel (University Medical Center Saarland, Germany) in the session "Clinical and public health perspectives in SLD: Detection, disparities, and treatment impact" (Hall 7 – Poster Stage 6). The study uses the Adelphi Real World MASH Disease Specific Programme, a cross-sectional physician survey from January to May 2024 with 65 physicians and 587 patients with MASH in Germany. Of the patients, 59% had fibrosis stage F0/F1, 40% F2/F3 and 1% F4. Obesity was present in 78% and type 2 diabetes in 49%; 73% had two or more cardiometabolic risk factors. Treatment rates were high, mainly with metformin, cardiovascular agents and GLP-1 receptor agonists, and the authors call for better treatment strategies for MASH with F2/F3 fibrosis regardless of diabetes status. Authors: M. Michel, M. J. Daumont, Y. Kim, M. Intorcia, H. Wallinger, J. Johnson. Several authors are employees of Madrigal Pharmaceuticals and Adelphi Real World.

Presentation IP431 at UEG Week 2026 by speaker Maurice Michel (University Medical Center Saarland, Germany): multidisciplinary clinics in MASLD and the integrated management of metabolic risk factors and liver disease. Tuesday, 20 October 2026, 10:00–11:00.

UEG Week 2027, the annual congress of United European Gastroenterology, takes place from 16 to 19 October 2027 at the Bella Center in Copenhagen, Denmark.